Find Paid Research Studies in Minnesota

Browse Locations ... United States» ... Minnesota

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Conditions: Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood
Interventions: Drug: Azacitidine; Drug: Fludarabine; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Gateway for Cancer Research; USC/Norris Comprehensive Cancer Center
Not yet recruiting - verified May 2013
Vigorous Exercise for Depressed Smokers

Conditions: Nicotine Dependence; Depression
Interventions: Behavioral: exercise; Behavioral: health education
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
A Phase I Study of iPS Cell Generation From Patients With COPD

Conditions: Thoracic Diseases; Respiratory Tract Diseases; Cancer of Lung; Cancer of the Lung; Lung Cancer; Lung Diseases, Obstructive; COPD; Pulmonary Emphysema; Neoplasms, Lung; Neoplasms, Pulmonary; Pulmonary Cancer; Pulmonary Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell
Intervention: Other: Skin Biopsy
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects

Conditions: Full Iris Defects; Partial Iris Defects
Intervention: Device: Artificial Iris (CustomFlex)
Sponsors: HumanOptics AG; HumanOptics AG
Not yet recruiting - verified May 2013
Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis

Condition: Cystic Fibrosis
Interventions: Drug: AquADEKs-2; Dietary Supplement: vitamins A, B, D, E, and K without added antioxidants
Sponsors: University of Colorado, Denver; University of Colorado, Denver; Cystic Fibrosis Foundation; Yasoo Health
Not yet recruiting - verified May 2013
Feasibility of Use of BariCare App in Pre-transplant Population

Conditions: Obesity; Pre-Renal Transplant Candidate; Pre-liver Transplant Candidate
Intervention: Behavioral: Use of smartphone app
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
BMN 110 US Expanded Access Program

Conditions: Mucopolysaccharidosis IVA; Morquio A Syndrome; MPS IVA
Intervention: Drug: BMN 110
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Available - verified May 2013
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Albuterol Spiromax®
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2013
Umbilical Cord Blood Collection and Processing for Cardiac Regeneration in Hypoplastic Left Heart Syndrome Patients

Condition: Hypoplastic Left Heart Syndrome (HLHS)
Intervention: Other: Collection of umbilical cord blood
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: GFF MDI (PT003); Drug: GP MDI (PT001); Drug: FF MDI (PT005); Drug: Placebo
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
Folic Acid and Zinc Supplementation Trial (FAZST)

Conditions: Pregnancy; Live Birth; Spontaneous Abortion
Interventions: Dietary Supplement: 5 mg folic acid and 30 mg elemental zinc; Drug: Placebo Comparator: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting - verified April 2013
Topiramate in Adolescents With Severe Obesity

Conditions: Obesity, Morbid; Obesity; Weight Loss
Interventions: Drug: Topiramate; Other: Placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting - verified May 2013
End-Tidal Carbon Dioxide as a Measure of Carboxyhemoglobin in Carbon Monoxide Poisoning

Condition: Carbon Monoxide Exposure
Intervention:
Sponsors: Minneapolis Medical Research Foundation; Minneapolis Medical Research Foundation
Recruiting - verified May 2013
NIRS Predict Low Cardiac Output State in Neonates and Infants in Cardiac Surgery

Condition: Congenital Heart Disease
Intervention: Device: EQUANOX Advance 8004CB sensor
Sponsors: Mayo Clinic; Mayo Clinic; Nonin Medical, Inc
Recruiting - verified May 2013
The Effect of Nasal Hair on Nasal Obstruction

Condition: Nasal Obstruction
Interventions: Procedure: Vibrissae trimming; Drug: Application of oxymetazoline
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2013
Impact of Prehabilitation in Total Knee Replacement

Condition: Total Knee Arthroplasty
Intervention: Other: Prehabilitation
Sponsors: Allina Health System; Allina Health System
Not yet recruiting - verified April 2013
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Subjects With Type 1 Diabetes (T1DM)

Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Drug: Pre-commercial formulation of Hylenex recombinant (hyaluronidase human injection); Procedure: Preadministration of commercial Hylenex® recombinant (hyaluronidase human injection); Procedure: Preadministration of pre-commercial Hylenex recombinant (hyaluronidase human injection); Device: Continuous Subcutaneous Insulin Infusion (CSII) via insulin infusion pumps
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified May 2013
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exendin 9,39; Drug: Placebo
Sponsors: Mayo Clinic; Adrian Vella; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Center for Research Resources (NCRR)
Recruiting - verified April 2013
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exendin 9, 39; Drug: Placebo
Sponsors: Mayo Clinic; Adrian Vella; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Center for Research Resources (NCRR)
Recruiting - verified April 2013
Study to Evaluate Safety & Efficacy of WC3011 in Postmenopausal Women With Dyspareunia

Condition: Vulvovaginal Atrophy
Interventions: Drug: Estradiol Vaginal Gel; Drug: Vehicle
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified April 2013
Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: carfilzomib; Drug: melphalan; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; Mayo Clinic
Not yet recruiting - verified April 2013
The Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo; Drug: Rifaximin
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified April 2013
MSC for Occlusive Disease of the Kidney

Conditions: Atherosclerotic Renal Artery Stenosis; Ischemic Nephropathy; Repair of Renal Microvasculature
Intervention: Drug: Arterial infusion of autologous mesenchymal stem cells
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: PEGPH20+nab-paclitaxel+gemcitabine; Drug: nab-paclitaxel + gemcitabine
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified April 2013
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QVA149; Drug: fluticasone/salmeterol
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013
Hippocampal Metabolism and Function in Patients With Type 1 Diabetes

Conditions: Hypoglycemia; Diabetes Mellitus
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting - verified May 2013
12 Week Efficacy and Safety Trial Followed by a 4 Week Withdrawal Period for Patients With Chronic Idiopathic Constipation

Condition: Chronic Idiopathic Constipation
Interventions: Drug: Elobixibat 10 mg; Drug: Elobixibat 5 mg; Drug: Placebo
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified May 2013
Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Condition: Type 2 Diabetes Mellitus (T2DM)
Interventions: Drug: PE0139 Injection; Drug: Placebo
Sponsors: PhaseBio Pharmaceuticals Inc.; PhaseBio Pharmaceuticals Inc.
Recruiting - verified May 2013
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy

Conditions: Muscular Dystrophy, Duchenne; Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn
Interventions: Drug: Ataluren; Drug: Placebo
Sponsors: PTC Therapeutics; PTC Therapeutics
Recruiting - verified April 2013
MIBG for Refractory Neuroblastoma and Pheochromocytoma

Conditions: Relapsed/Refractory Neuroblastoma; Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131I-MIBG); Drug: Potassium iodide solution; Drug: G-CSF
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified May 2013
Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Conditions: HIV; HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Vaginal Bromocriptine for Treatment of Adenomyosis

Condition: Adenomyosis
Intervention: Drug: Vaginal Bromocriptine
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis

Condition: Psoriasis
Interventions: Drug: MOL4239; Drug: Placebo
Sponsors: Moleculin, LLC; Moleculin, LLC
Recruiting - verified May 2013
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Conditions: Insular Thyroid Cancer; Recurrent Thyroid Cancer; Stage I Follicular Thyroid Cancer; Stage I Papillary Thyroid Cancer; Stage II Follicular Thyroid Cancer; Stage II Papillary Thyroid Cancer; Stage III Follicular Thyroid Cancer; Stage III Papillary Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer; Stage IVB Papillary Thyroid Cancer; Stage IVC Follicular Thyroid Cancer; Stage IVC Papillary Thyroid Cancer
Interventions: Drug: cabozantinib-s-malate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified March 2013
Functional Magnetic Resonance Imaging (fMRI) During Deep Brain Stimulation (DBS) to Treat Parkinson's Disease

Condition: Parkinson Disease
Intervention: Procedure: Functional Magnetic Resonance Imaging (fMRI)
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2013
Clinical Trial Nuedexta in Subjects With ALS

Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: Nuedexta; Drug: Matching Placebo
Sponsors: Center for Neurologic Study, La Jolla, California,; Center for Neurologic Study, La Jolla, California,; ALS Association; State University of New York - Upstate Medical University
Recruiting - verified May 2013
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)

Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076 AM1)

Condition: Osteoporosis
Interventions: Drug: odanacatib; Other: placebo to odanacatib
Sponsors: Merck; Merck
Recruiting - verified May 2013
Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RO5452802; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

Conditions: Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Diffuse Large B-cell Lymphoma; Indolent Non-Hodgkin's Lymphoma
Intervention: Drug: GS-9973
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Giant Cell Arteritis

Condition: Giant Cell Arteritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab placebo; Drug: prednisone; Drug: prednisone placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2013
Arthrex Eclipse™ Shoulder Prosthesis

Condition: Osteoarthritis
Interventions: Device: Univers™; Device: Eclipse™ Total Shoulder Replacement
Sponsors: Arthrex, Inc.; Arthrex, Inc.
Recruiting - verified May 2013
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Ibrutinib; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2013
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma

Condition: Carcinoma, Hepatocellular
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2013
A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Condition: Gastric Cancer
Interventions: Drug: pertuzumab [Perjeta]; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: cisplatin; Drug: capecitabine; Drug: 5-fluorouracil
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; National Surgical Adjuvant Breast and Bowel Project (NSABP); German Breast Group
Recruiting - verified May 2013
Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

Condition: Squamous Non Small Cell Lung Cancer
Interventions: Drug: Necitumumab; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: BMS-986020; Drug: Placebo matching with BMS-986020
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

Conditions: Amnestic Mild Cognitive Impairment; Alzheimer's Disease
Interventions: Drug: Insulin (Humulin® R U-100); Drug: Placebo
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS)
Not yet recruiting - verified May 2013
A Study Using MABp1 To Increase Overall Survival In Patients With Colorectal Cancer And Weight Loss

Conditions: Metastatic Colorectal Cancer; Cachexia; Weight Loss
Interventions: Drug: MABp1; Drug: Megestrol Acetate
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2013
Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study

Condition: Obesity
Interventions: Device: Aspiration Therapy (AspireAssist); Behavioral: Lifestyle Therapy
Sponsors: Aspire Bariatrics, Inc.; Aspire Bariatrics, Inc.; Boston Medical Center; Brigham and Women's Hospital; Cornell University; Howard University; Mayo Clinic; Northwestern University; St. Mary Medical Center; San Diego Veterans Healthcare System; University of Pennsylvania; Washington University School of Medicine
Recruiting - verified May 2013
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Drug: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally)
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Condition: Metastatic or Unresectable Cutaneous Melanoma
Interventions: Drug: MEK162; Drug: Dacarbazine
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013
Long-Term Outcome Following the Treatment of Pediatric Scoliosis

Condition: Adolescent Idiopathic Scoliosis
Intervention: Other: Long-term outcomes
Sponsors: Mayo Clinic; Mayo Clinic; Scoliosis Research Society
Recruiting - verified May 2013
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

Condition: Asthma
Interventions: Drug: Albuterol Spiromax® 90 mcg/inhalation; Drug: Placebo Spiromax
Sponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: Treosulfan
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; medac GmbH
Not yet recruiting - verified May 2013
A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

Condition: Dry Eye
Interventions: Drug: Lifitegrast; Drug: Placebo
Sponsors: SARcode Bioscience; SARcode Bioscience
Recruiting - verified May 2013
C-Pulse® System: A Heart Assist Device Clinical Study

Condition: Heart Failure
Intervention: Device: C-Pulse® System Counterpulsation
Sponsors: Sunshine Heart Inc.; Sunshine Heart Inc.
Recruiting - verified May 2013
Efficacy and Safety of ISIS TTR Rx in Familial Amyloid Polyneuropathy

Condition: Familial Amyloid Polyneuropathy
Interventions: Drug: ISIS TTR Rx; Drug: Placebo
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals; GlaxoSmithKline
Recruiting - verified April 2013
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013
Maternal and Neurodevelopmental Outcomes of in Utero Antiepileptic Drug (AED) Exposure

Conditions: Epilepsy; Pregnancy
Intervention:
Sponsors: Emory University; Emory University; The EMMES Corporation
Recruiting - verified April 2013
Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: tivantinib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
A Pharmacokinetic/Pharmacodynamic Study of Tamiflu (Oseltamivir) in Immunocompromised Children With Confirmed Influenza Infection

Condition: Influenza
Interventions: Drug: oseltamivir [Tamiflu]; Drug: oseltamivir [Tamiflu]; Drug: oseltamivir [Tamiflu]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Metformin; Other: Placebo Comparator
Sponsors: Mayo Clinic; Mayo Clinic; Alliance for Clinical Trials in Oncology
Recruiting - verified May 2013
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Condition: Atrial Fibrillation
Interventions: Drug: rivaroxaban; Drug: uninterrupted vitamin K antagonist (VKA)
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC
Recruiting - verified May 2013
Clomiphene Citrate Fast-Track Protocol for Fertility Treatment in Women With PCOS

Conditions: Polycystic Ovary Syndrome; Infertility
Interventions: Drug: Progestin; Drug: Clomiphene Citrate
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
Versartis Trial in Children to Assess Long-Acting Growth Hormone

Condition: Pediatric Growth Hormone Deficiency
Intervention: Drug: Experimental: VRS-317
Sponsors: Versartis Inc.; Versartis Inc.
Recruiting - verified May 2013
Stress Management for Couples Undergoing In Vitro Fertilization (IVF)

Condition: Infertility
Interventions: Behavioral: Stress Management & Resiliency Training; Behavioral: Stress Management DVD
Sponsors: Mayo Clinic; Amit Sood
Recruiting - verified May 2013
VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Condition: Postmenopausal Osteoporosis
Interventions: Drug: Teriparatide; Drug: Risedronate; Drug: Placebo; Drug: Calcium; Drug: Vitamin D
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Conditions: Recurrent Melanoma; Recurrent Thyroid Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified May 2013
A Prospective Study of Patients With Hypoplastic Left Heart Syndrome (HLHS) Following Stage II Surgical Palliation

Condition: Hypoplastic Left Heart Syndrome
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Condition: Primary Amyloidosis
Intervention: Drug: NEOD001
Sponsors: Onclave Therapeutics Limited, a wholly-owned subsidiary of Prothena Corporation plc; Onclave Therapeutics Limited, a wholly-owned subsidiary of Prothena Corporation plc
Recruiting - verified May 2013
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

Condition: Cystic Fibrosis
Intervention: Drug: ivacaftor
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013
Neurotransmitter Measurements Using Wireless Instantaneous Neurotransmitter Concentration System (WINCS) During Deep Brain Stimulation Neurosurgery

Conditions: Essential Tremor; Parkinson's Disease; Dystonia
Intervention: Device: WINCS (Wireless Instantaneous Neurochemical Concentration Sensing System)
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2013
Feasibility of Use of BariCare App in Pre-bariatric Surgery.

Condition: Obesity
Intervention: Behavioral: Use of smartphone app
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy

Condition: Epilepsy
Intervention: Procedure: Laser ablation
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2013
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

Conditions: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
Interventions: Biological: MK-8237 tablets; Biological: Placebo tablets; Drug: Rescue Medication: Self-Injectable Epinephrine; Drug: Rescue Medication: Loratadine tablets; Drug: Rescue Medication: Olopatadine ophthalmic drops; Drug: Rescue Medication: Mometasone furoate nasal spray
Sponsors: Merck; Merck
Recruiting - verified May 2013
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Condition: Malignant Melanoma
Intervention: Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Condition: Gastric Cancer
Interventions: Drug: Rilotumumab; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

Condition: Cystic Fibrosis
Interventions: Biological: KB001-A; Biological: Placebo Comparator
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified May 2013
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Conditions: For Donors:; Related Donors Donating PBSC to a Family Member; For Recipients:; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Chronic Lymphocytic Leukemia
Intervention: Drug: Plerixafor
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Genzyme; Sanofi
Recruiting - verified May 2013
A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Biological: AMG 181; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma

Condition: Asthma
Interventions: Drug: Mepolizumab; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet

Condition: Analgesia
Intervention: Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin; Drug: placebo
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified May 2013
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: vemurafenib; Drug: Placebo; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (Mcg) , FF/VI 100/25 Mcg, and FF 100 Mcg in Adults and Adolescents With Persistent Asthma.

Condition: Asthma
Interventions: Drug: Fluticasone Furoate/ Vilanterol 200/25 mcg; Drug: Fluticasone Furoate/ Vilanterol 100/25 mcg; Drug: Fluticasone Furoate 100 mcg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study of Evacetrapib in High-Risk Vascular Disease

Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified May 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Conditions: Hepatitis C; Cirrhosis; Portal Hypertension; With or Without Liver Decompensation
Interventions: Drug: GS-7977; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Conditions: Prostate Cancer; Metastatic Castrate-Resistant Prostate Cancer; PSA
Interventions: Drug: OGX-427; Drug: Abiraterone Acetate; Drug: Prednisone
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; OncoGenex Technologies
Recruiting - verified May 2013
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Condition: Narcolepsy
Interventions: Drug: ADX-N05; Drug: Placebo
Sponsors: Aerial BioPharma, LLC; Aerial BioPharma, LLC
Recruiting - verified May 2013
Investigation of Sacroiliac Fusion Treatment (INSITE)

Conditions: Degenerative Sacroiliitis; Sacroiliac Joint Disruption
Interventions: Device: iFuse Implant System; Other: Non-surgical management
Sponsors: SI-BONE, Inc.; SI-BONE, Inc.
Recruiting - verified May 2013
Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function

Condition: "Cardiorenal Syndrome (CRS)"
Interventions: Drug: Candesartan; Drug: Placebo
Sponsors: Mayo Clinic; Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2013
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Condition: Diabetes Melliuts, Type 2
Interventions: Other: Placebo; Drug: 25 mg PF-05231023; Drug: 50 mg PF-05231023; Drug: 100 mg PF-05231023; Drug: 150 mg PF-05231023
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

Condition: Ischemic Dilated Cardiomyopathy (IDCM)
Interventions: Biological: ixmyelocel-T; Other: Vehicle Control
Sponsors: Aastrom Biosciences; Aastrom Biosciences
Recruiting - verified May 2013
A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive-Compulsive Disorder

Condition: Obsessive-Compulsive Disorder
Interventions: Drug: bitopertin; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2013
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: pegylated liposomal doxorubicin (PLD); Drug: VTX-2337; Drug: Placebo
Sponsors: VentiRx Pharmaceuticals Inc.; VentiRx Pharmaceuticals Inc.; Gynecologic Oncology Group
Recruiting - verified April 2013
An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls

Condition: Transplantation, Cytomegalovirus Infections
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727) (ODYSSEY Outcomes)

Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
Phase II Phosphatidylinositol 3-Kinase (PI3K) Inhibitor in Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (NHL)

Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified April 2013
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

Conditions: Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: FOLFOX regimen; Drug: selumetinib
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Cardiopulmonary Exercise Testing in Cirrhotic Patients: a Pilot Study

Condition: End Stage Liver Disease
Intervention: Other: cardiopulmonary exercise testing
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Condition: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: Drug: MLN9708; Drug: Dexamethasone; Drug: Melphalan; Drug: Cyclophosphamide; Drug: Thalidomide; Drug: Lenalidomide
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2013
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

Conditions: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Neurofibrosarcoma; Chondrosarcoma; Endometrial Stromal Sarcoma; Mast Cell Sarcoma; Metastatic Adult Malignant Fibrous Histiocytoma of Bone; Ovarian Carcinosarcoma; Ovarian Sarcoma; Recurrent Adult Malignant Fibrous Histiocytoma of Bone; Recurrent Adult Soft Tissue Sarcoma; Small Intestine Leiomyosarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer

Conditions: Cervical Cancer; Lymphedema; Sexuality and Reproductive Issues
Interventions: Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cone biopsy; Procedure: genitourinary surgical procedure; Procedure: loop electrosurgical excision procedure; Procedure: quality-of-life assessment; Procedure: therapeutic laparoscopic surgery; Procedure: therapeutic lymphadenectomy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Efficacy at 16 Weeks and Long Term Efficacy, Safety and Tolerability up to 5 Years of Secukinumab in Patients With Active Ankylosing Spondylitis

Condition: Ankylosing Spondylitis
Interventions: Biological: AIN457; Biological: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified May 2013
Adult Congenital Heart Disease Registry (QuERI)

Conditions: Pulmonary Arterial Hypertension; Congenital Heart Disease
Intervention: Other: observational
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

Condition: Infections
Interventions: Drug: Ceftaroline fosamil; Drug: Ceftriaxone plus vancomycin
Sponsors: Cerexa, Inc.; Cerexa, Inc.; AstraZeneca
Recruiting - verified May 2013
Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib and HU-placebo; Drug: HU and ruxolitinib-placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

Conditions: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Intervention: Drug: asparaginase Erwinia chrysanthemi
Sponsors: EUSA Pharma (US), Inc.; EUSA Pharma (US), Inc.
Recruiting - verified May 2013
National Parkinson Foundation Quality Improvement Initiative

Condition: Parkinson's Disease
Intervention:
Sponsors: National Parkinson Foundation; National Parkinson Foundation
Recruiting - verified May 2013
Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

Conditions: Lysosomal Storage Disease; Peroxisomal Disorder
Interventions: Drug: Campath-1H; Drug: Clofarabine; Drug: Melphalan; Radiation: Total Body Irradiation with Marrow Boosting; Biological: Hematopoietic stem cell transplantation; Drug: Cyclosporine A; Drug: Mycophenolate mofetil
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2013
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery

Conditions: Adult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: trebananib; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: BIBF 1120
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

Condition: Herpes Zoster (HZ)
Interventions: Biological: Herpes Zoster vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

Condition: Coronary Artery Disease (CAD)
Intervention: Drug: Regadenoson
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.
Recruiting - verified May 2013
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

Condition: Acute Kidney Injury
Interventions: Biological: AC607; Biological: Vehicle Only
Sponsors: AlloCure Inc.; AlloCure Inc.
Recruiting - verified May 2013
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Condition: Melanoma
Interventions: Drug: Dabrafenib; Drug: Vemurafenib; Drug: Trametinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Eisenmenger Quality Enhancement Research Initiative

Condition: Eisenmenger
Intervention: Other: Management
Sponsors: Actelion; Actelion
Recruiting - verified May 2013
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Condition: Hypercholesterolemia
Interventions: Drug: PBO; Drug: 200mg PF-04950615 (RN316); Drug: 300mg PF-04950615 (RN316); Drug: PBO; Drug: PF-04950615; Drug: PF-04950615; Drug: PF-04950615
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Condition: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified May 2013
A Clinical Trial for the Surgical Treatment of Elderly Distal Radius Fractures

Condition: Distal Radius Fracture
Interventions: Procedure: Open Reduction and Internal Fixation; Procedure: External Fixation; Procedure: Percutaneous Pinning; Procedure: Closed Reduction and casting
Sponsors: University of Michigan; University of Michigan; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging (NIA)
Recruiting - verified May 2013
Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network

Conditions: MPS I; MPS II; MPS VI; Mucopolysaccharidoses
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Rare Diseases Clinical Research Network; National Center for Advancing Translational Science (NCATS); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2013
International Guillain-Barré Syndrome Outcome Study

Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2013
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified May 2013
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

Conditions: Primary Immunodeficiency; Agammaglobulinemia; Hypogammaglobulinemia; Antibody Deficiency
Intervention: Biological: Kedrion IVIG 10%
Sponsors: Kedrion S.p.A.; Kedrion S.p.A.
Recruiting - verified May 2013
Driveline Silicone Skin Interface Registry

Condition: Driveline Heart-assisted Device Related Infection
Intervention:
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition: Smoking Cessation
Interventions: Drug: placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.
Recruiting - verified May 2013
Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation

Condition: Menorrhagia
Interventions: Device: Aurora Endometrial Ablation; Device: Rollerball Ablation/Resection
Sponsors: Minerva Surgical, Inc.; Minerva Surgical, Inc.
Recruiting - verified May 2013
CentriMag RVAS U.S. Post-approval Study Protocol

Condition: Right Ventricular Failure
Intervention: Device: CentriMag RVAS placement
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Recruiting - verified April 2013
The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Conditions: Relapsed Multiple Myeloma; Refractory Multiple Myeloma
Interventions: Drug: MLN9708 + Lenalidomide + Dexamethasone; Drug: Placebo + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2013
Evaluation of Patient Reported Outcome Instruments in Celiac Disease Patients

Condition: Celiac Disease
Intervention:
Sponsors: Alvine Pharmaceuticals Inc.; Alvine Pharmaceuticals Inc.
Recruiting - verified May 2013
Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia

Condition: Myocardial Ischemia
Interventions: Device: ADRCs processed by the Celution System; Device: Placebo Comparator: Lactated Ringer's and Subject's Blood
Sponsors: Cytori Therapeutics; Cytori Therapeutics
Recruiting - verified April 2013
Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel

Conditions: Pain; Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo; Other: questionnaire administration
Sponsors: Academic and Community Cancer Research United; Academic and Community Cancer Research United
Recruiting - verified April 2013
Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease

Condition: Parkinson's Disease
Intervention: Drug: nicotine transdermal patch
Sponsors: University of Vermont; James BOYD MD; Michael J. Fox Foundation for Parkinson's Research
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: Ustekinumab 45 mg; Drug: Ustekinumab 90 mg; Drug: Placebo
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013
Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Conditions: Type 2 Diabetes Mellitus; Renal Impairment
Interventions: Drug: LX4211; Drug: LX4211 Placebo
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified May 2013
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2013
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

Conditions: HIV Infection; HIV Infections
Interventions: Drug: Losartan; Drug: Placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Merck
Not yet recruiting - verified May 2013
Mechanism and Repository Study for the Red Cell Storage Duration Study

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Intervention:
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Phase 1/2, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients With Advanced Cancers

Conditions: Advanced Cancers; DLBCL; Lymphoma
Intervention: Drug: ISIS-STAT3Rx
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals; AstraZeneca
Recruiting - verified April 2013
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Conditions: Neovascular Age-elated Macular Degeneration (Wet AMD); Exudative Macular Degeneration
Interventions: Drug: LFG316; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations

Condition: Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: Academic and Community Cancer Research United; Academic and Community Cancer Research United
Recruiting - verified May 2013
Cervicogenic Headache Dose-Response

Condition: Cervicogenic Headache
Interventions: Other: Spinal Manipulation; Other: Light Massage
Sponsors: University of Western States; University of Western States; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified May 2013
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Carboplatin; Biological: Autologous stem cell infusion; Biological: Granulocyte colony stimulating factor; Radiation: Radiation therapy; Drug: Isotretinoin (13-cis-retinoic acid); Drug: Melphalan; Drug: Etoposide
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2013
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified May 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013
Natural History and Treatment Outcomes(Changes) in Fabry Renal Disease Study

Condition: Fabry Disease
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Rare Diseases Clinical Research Network; National Center for Advancing Translational Science (NCATS); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Washington University School of Medicine; Haukeland University Hospital
Recruiting - verified May 2013
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Condition: Type 2 Diabetes
Interventions: Drug: "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)]; Drug: Insulin glargine, metformin, prandial insulin
Sponsors: University of Washington; University of Washington; Eli Lilly and Company; Sanofi; Bristol-Myers Squibb; DexCom, Inc.; Bayer; Medicomp; University of Texas; Department of Veterans Affairs; Biomedical Research Institute of New Mexico
Recruiting - verified May 2013
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

Conditions: Chronic Myocardial Ischemia; Refractory Angina Pectoris; (Advanced) Coronary Heart Disease
Interventions: Biological: Auto-CD34+ cells; Biological: Placebo: Diluent used to suspend Auto-CD34+ cells; Other: Standard of care
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2013
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Conditions: Liposarcoma; Surgically Unresectable Liposarcoma; Metastatic Liposarcoma
Intervention: Drug: pazopanib
Sponsors: ACORN Research, LLC; ACORN Research, LLC; GlaxoSmithKline
Recruiting - verified May 2013
Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004 AM2)

Condition: Intra-abdominal Infections
Interventions: Drug: MK-7655 250 mg with imipenem/cilastatin; Drug: MK-7655 125 mg with imipenem/cilastatin; Drug: imipenem/cilastatin with placebo; Drug: Matching placebo to MK-7655
Sponsors: Merck; Merck
Recruiting - verified May 2013
LIPS-A: Lung Injury Prevention Study With Aspirin

Condition: Acute Respiratory Distress Syndrome
Interventions: Drug: Aspirin; Drug: Lactose powder
Sponsors: Mayo Clinic; Ognjen Gajic; Beth Israel Deaconess Medical Center; Montefiore Medical Center; Vanderbilt University
Recruiting - verified April 2013
A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223 AM2)

Condition: Asthma
Interventions: Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg; Drug: Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg; Drug: Placebo Metered Dose Inhaler (MDI); Drug: Placebo Dry Powder Inhaler (DPI)
Sponsors: Merck; Merck
Recruiting - verified May 2013
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (CZP + MTX); Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified May 2013
A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections

Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified April 2013
AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified February 2013
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Conditions: Metastatic Colorectal Cancer; Colorectal Cancer
Interventions: Drug: MORAb-004; Drug: Placebo
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2013
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

Condition: Colorectal Cancer Metastatic
Intervention: Device: TheraSphere
Sponsors: Nordion (Canada) Inc.; Nordion (Canada) Inc.
Recruiting - verified May 2013
ATLAS - Anti-Tweak in Lupus Nephritis Patients

Condition: Lupus Nephritis
Interventions: Drug: BIIB023; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Biogen Idec Australia Pty Ltd; Biogen Idec Research Ltd.; Biogen Idec MA Inc.
Recruiting - verified April 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified April 2013
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Condition: Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac; Drug: Eflornithine and Placebo; Drug: Sulindac and Placebo
Sponsors: Cancer Prevention Pharmaceuticals, Inc.; Cancer Prevention Pharmaceuticals, Inc.
Not yet recruiting - verified May 2013
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Condition: Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: nab-paclitaxel; Drug: FOLFIRINOX; Genetic: Immunohistochemistry (IHC) Analysis; Drug: Metformin
Sponsors: Pancreatic Cancer Research Team; Pancreatic Cancer Research Team
Recruiting - verified September 2012
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Conditions: Hypercholesterolemia; Coronary Heart Disease
Interventions: Drug: mipomersen sodium 200 mg; Drug: Placebo; Drug: mipomersen sodium 70 mg
Sponsors: Genzyme; Genzyme
Recruiting - verified May 2013
Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)

Conditions: Anticoagulation; Left Ventricular Assist Device
Intervention:
Sponsors: Thoratec Europe Ltd; Thoratec Europe Ltd; Thoratec Corporation
Recruiting - verified May 2013
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Conditions: Heart Failure; Cardiac Failure; Acute Decompensated Heart Failure (ADHF)
Interventions: Device: Isolated veno-venous ultrafiltration (AQ); Drug: IV Loop Diuretics (LD)
Sponsors: Gambro Renal Products, Inc.; Gambro Renal Products, Inc.; Gambro UF Solutions, Inc.
Recruiting - verified May 2013
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Merck; Merck
Recruiting - verified May 2013
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD treatment; Other: Standard of care (Control)
Sponsors: Vital Therapies, Inc.; Vital Therapies, Inc.
Recruiting - verified April 2013
A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Condition: Ovarian Cancer, Pancreatic Cancer
Intervention: Drug: DMOT4039A
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
GLORIA-AF Registry Program - Second and Third Phases

Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Interventions: Drug: brentuximab vedotin; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
A Study Of Oral CP-690550 As A Maintenance Therapy For Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis

Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study Of Dacomitinib In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib Plus Blinded Doxycycline or Placebo; Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream; Drug: Dacomitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)

Condition: Paroxysmal Atrial Fibrillation
Interventions: Device: EAS-AC (HeartLight); Procedure: Control Arm Ablation
Sponsors: CardioFocus; CardioFocus
Recruiting - verified April 2013
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2013
Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Condition: Crohn's Disease
Intervention: Drug: Entocort
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

Condition: Heart Failure
Interventions: Device: HM II (HeartMate II LVAD); Drug: OMM (Optimal Medical Management)
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Conditions: CD27 Expressing B-cell Malignancies; CD27 Expressing Solid Tumors; Chronic Lymphocytic Leukemia; Burkett's Lymphoma; Mantle Cell Lymphoma; Primary Lymphoma of the Central Nervous System; Marginal Zone B Cell Lymphoma; Solid Tumor; Metastatic Melanoma; Renal (Clear) Cell Carcinoma; Hormone-refractory Prostate Adenocarcinoma; Ovarian Cancer; Colorectal Adenocarcinoma; Non-small Cell Lung Cancer; Melanoma (Solid Tumor Expansion Arm Only)
Intervention: Drug: CDX-1127
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: LGH447
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

Condition: Pulmonary Emphysema
Interventions: Device: Treatment plus Optimal Medical Therapy; Other: Optimal Medical Therapy
Sponsors: Aeris Therapeutics; Aeris Therapeutics
Recruiting - verified May 2013
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Drug: MEDI-551; Drug: Rituximab; Drug: ICE; Drug: DHAP; Procedure: Autologous Stem Cell Transplant (ASCT)
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2013
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 + MCV4 + Tdap; Biological: MCV4 + Tdap + saline; Biological: rLP2086 + saline
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 and Gardasil; Biological: rLP2086; Biological: Gardasil
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Safety Study of Entocort for Children With Crohn's Disease

Condition: Crohn's Disease
Intervention: Drug: Entocort
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

Conditions: Coronary Artery Disease; Angina Pectoris
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Open Label Study of Long Term Evaluation Against LDL-C Trial

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

Conditions: Keratoconus; Corneal Ectasia
Interventions: Device: KXL System (15 mW/cm2); Device: KXL System (30 mW/cm2); Device: KXL System (45 mW/cm2); Drug: riboflavin ophthalmic solution
Sponsors: ACOS; ACOS
Recruiting - verified May 2013
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Condition: Neoplasms
Interventions: Drug: Gemcitabine; Drug: BAY80-6946; Drug: Cisplatin; Drug: NaCl; Drug: BAY80-6964 fixed dose
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: Alliance for Clinical Oncology Trials; North Central Cancer Treatment Group; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified January 2013
The "Virtual" Multicenter Spontaneous Coronary Artery Dissection (SCAD) Registry

Conditions: Spontaneous Coronary Artery Dissection; SCAD
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)

Conditions: Spontaneous Coronary Artery Dissection; SCAD
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
A Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma

Conditions: Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin; Drug: rituximab
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3)

Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2013
Blood Tests to Study Injury Severity and Outcome in Traumatic Brain Injury Patients

Condition: Traumatic Brain Injury
Intervention:
Sponsors: Emory University; Emory University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Hydrogel Endovascular Aneurysm Treatment Trial

Condition: Cerebral Aneurysm
Interventions: Device: HydroCoil Embolic System; Device: Control (bare platinum coils)
Sponsors: Northwestern University; Northwestern University; MicroVention, Inc
Recruiting - verified May 2013
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Condition: Primary Biliary Cirrhosis
Interventions: Drug: ustekinumab (double-blind); Drug: ustekinumab (double-blind); Drug: ustekinumab (open-label); Drug: ustekinumab (double-blind); Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Conditions: Cognitive/Functional Effects; Fatigue; Neurotoxicity; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Therapy-related Toxicity; Waldenström Macroglobulinemia
Interventions: Drug: temsirolimus; Biological: rituximab; Drug: bortezomib; Drug: dexamethasone
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B

Condition: Hepatitis B
Intervention: Drug: Entecavir and peginterferon
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Recruiting - verified April 2013
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B

Condition: Hepatitis B
Interventions: Drug: Tenofovir; Drug: Combination of peginterferon alfa 2a and tenofovir
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Recruiting - verified April 2013
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection

Condition: Hepatitis B
Intervention: Drug: Entecavir and peginterferon
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2013
The Evaluation of VAD InterVEntion Before Inotropic Therapy

Condition: Congestive Heart Failure
Interventions: Device: HM II® (HeartMate II® LVAD); Other: OMM (Optimal Medical Management)
Sponsors: University of Michigan; University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); Thoratec Corporation
Not yet recruiting - verified May 2013
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified May 2013
A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age

Conditions: Acute Myeloid Leukemia; Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine-single agent; Drug: Lenalidomide - single agent; Drug: Lenalidomide in combination with azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Conditions: Recurrent Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: Drug: Akt inhibitor MK2206; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
S0820, Adenoma and Second Primary Prevention Trial

Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo; Drug: eflornithine & sulindac placebo; Drug: Eflornithine placebo & sulindac; Drug: Eflornithine plus sulindac
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.
Recruiting - verified May 2013
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified April 2013
Patients Treated for SCID (1968-2010)

Conditions: SCID; ADA-SCID; XSCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With Ccr5 Tropic HIV 1

Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2013
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Conditions: Extra-adrenal Paraganglioma; Metastatic Pheochromocytoma; Paraganglioma; Recurrent Pheochromocytoma
Interventions: Drug: pazopanib hydrochloride; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

Condition: Multicentric Castleman's Disease
Intervention: Drug: Siltuximab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

Condition: Cancer
Intervention: Drug: GSK2118436
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Conditions: Chondrosarcoma; Metastatic Chondrosarcoma
Intervention: Drug: pazopanib
Sponsors: ACORN Research, LLC; ACORN Research, LLC; GlaxoSmithKline
Recruiting - verified May 2013
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified April 2013
Pilon Fracture Reduction and Functional Outcome

Condition: Pilon Fracture of Tibia
Intervention:
Sponsors: AO Clinical Investigation and Documentation; AO Clinical Investigation and Documentation
Recruiting - verified April 2013
Clinical Study of PM01183 in Patients With Acute Leukemia

Condition: Acute Leukemia
Intervention: Drug: PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion
Sponsors: PharmaMar; PharmaMar
Recruiting - verified May 2013
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: GSK1605786A; Drug: Placebo; Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Open-Label Extension Study of GSK1605786A

Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

Conditions: Graft Versus Host Disease; Systemic Scleroderma
Interventions: Drug: imatinib mesylate; Biological: rituximab; Other: questionnaire administration; Procedure: biopsy; Other: cytology specimen collection procedure
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2013
Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

Condition: Bronchiolitis Obliterans
Interventions: Drug: fluticasone propionate; Drug: montelukast sodium; Procedure: pulmonary function testing; Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Genetic: protein analysis; Drug: azithromycin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2013
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2013
INcrease Of VAgal TonE in CHF

Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Myelodysplasia
Interventions: Biological: human myeloid progenitor cells; Drug: G-CSF
Sponsors: Cellerant Therapeutics; Cellerant Therapeutics; Department of Health and Human Services
Recruiting - verified May 2013
Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Condition: Cancer, Solid Tumor
Interventions: Drug: lambrolizumab 1 mg/kg; Drug: lambrolizumab 3 mg/kg; Drug: lambrolizumab 10 mg/kg; Drug: lambrolizumab MEL; Drug: lambrolizumab NSCLC; Drug: lambrolizumab MEL Low Dose; Drug: lambrolizumab MEL High Dose; Drug: lambrolizumab NSCLC Low Dose; Drug: lambrolizumab NSCLC High Dose; Drug: lambrolizumab NSCLC Medium Dose
Sponsors: Merck; Merck
Recruiting - verified May 2013
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified May 2013
A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Condition: Lymphoma, B-Cell
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: CHOP chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Fondazione Italiana Linfomi ONLUS
Recruiting - verified May 2013
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Conditions: Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma
Interventions: Biological: ofatumumab; Drug: bendamustine hydrochloride; Drug: bortezomib; Other: laboratory biomarker analysis; Procedure: positron emission tomography with radiolabeled targeting agents; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study To Monitor Long-Term Treatment With PF-00547659

Condition: Crohn's Disease
Intervention: Drug: PF-00547659
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2013
TRINOVA-2: Trebananib in Ovarian Cancer-2

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG386 plus PLD; Drug: Placebo plus PLD
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Environmental Risk Factors for the Anti-synthetase Syndrome

Condition: Myositis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified May 2013
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection; Drug: PF-00547659 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Conditions: Dysphagia; Lung Cancer; Pain
Interventions: Drug: Manuka honey; Drug: chemotherapy; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

Conditions: Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Biological: cetuximab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM3)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Conditions: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: bicalutamide; Other: clinical observation
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)

Condition: Critical Limb Ischemia
Interventions: Device: BMAC injection; Device: Placebo injection
Sponsors: Harvest Technologies; Harvest Technologies
Recruiting - verified April 2013
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2013
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Conditions: Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Spinal Cord Neoplasm; Untreated Childhood Brain Stem Glioma; Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat; Biological: bevacizumab; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013
Alzheimer's Disease Neuroimaging Initiative 2

Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2013
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

Conditions: Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Adult Diffuse Mixed Cell Lymphoma; Adult Diffuse Small Cleaved Cell Lymphoma; Adult Grade III Lymphomatoid Granulomatosis; Adult Immunoblastic Large Cell Lymphoma; Adult Lymphoblastic Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia With Nodal Disease
Interventions: Biological: dendritic cell vaccine therapy; Procedure: cryotherapy; Biological: pneumococcal polyvalent vaccine; Other: laboratory biomarker analysis; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Biological: autologous dendritic cell-tumor fusion vaccine
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2013
IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction

Conditions: Acute Myocardial Infarction; Congestive Heart Failure; ST-Elevation Myocardial Infarction
Interventions: Device: Sodium Alginate and Calcium Gluconate; Device: Saline Solution
Sponsors: Ikaria Holdings Inc.; Ikaria Holdings Inc.
Recruiting - verified May 2013
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Condition: Portopulmonary Hypertension
Intervention: Drug: Ambrisentan
Sponsors: Tufts Medical Center; Tufts Medical Center; Gilead Sciences
Recruiting - verified May 2013
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Condition: Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2013
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Condition: Ischemic Stroke
Interventions: Drug: PF-03049423; Drug: PF-03049423; Drug: PF-03049423; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

Conditions: Graft vs Host Disease; Cutaneous Sclerosis; Bronchiolitis Obliterans
Intervention:
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified April 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Pharmacogenomic Evaluation of Antihypertensive Responses 2

Condition: Hypertension
Intervention: Drug: metoprolol or chlorthalidone
Sponsors: National Institute of General Medical Sciences (NIGMS); National Institute of General Medical Sciences (NIGMS)
Recruiting - verified May 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Natural History Study of SCID Disorders

Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Condition: Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Temozolomide; Radiation: Irradiation
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Children's Hospital Boston; University of California, San Francisco; Ann & Robert H Lurie Children's Hospital of Chicago; Children's Healthcare of Atlanta; Children's Hospital Colorado; Children's Hospital Los Angeles; Children's Hospital of Michigan; Children's Hospitals and Clinics of Minnesota; Cook Children's Medical Center; Doernbecher Children's Hospital; Duke University; Johns Hopkins University; Memorial Sloan-Kettering Cancer Center; Miami Children's Hospital; New York University; Penn State Hershey Medical Center; Seattle Children's; University of Louisville; University of Mississippi Medical Center; UT Southwestern Medical Center; Washington University Medical Center
Recruiting - verified May 2013
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II)

Condition: Intracerebral Hemorrhage
Intervention: Drug: Nicardipine hydrochloride
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2013
Nephrotic Syndrome Study Network

Conditions: Minimal Change Disease (MCD); Membranous Nephropathy; Glomerulosclerosis, Focal Segmental
Intervention:
Sponsors: University of Michigan; University of Michigan; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The NephCure Foundation
Recruiting - verified April 2013
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Contrast Media Reduction and Removal in Patients With CKD (PRESERV)

Condition: Contrast Induced Nephropathy
Interventions: Device: CINCOR™ System; Drug: Peri-procedural hydration
Sponsors: Osprey Medical, Inc; Osprey Medical, Inc
Recruiting - verified April 2013
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2013
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Condition: Ulcerative Colitis
Intervention: Drug: Amg 181
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

Condition: Bladder Cancer Requiring Cystectomy
Interventions: Other: Quality of Life Questionnaires; Other: Get up and Go test; Other: Hand Grip test
Sponsors: University of Miami; University of Miami; National Cancer Institute (NCI)
Recruiting - verified April 2013
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Metastatic Intraocular Melanoma; Recurrent Intraocular Melanoma
Interventions: Drug: selumetinib; Drug: temozolomide; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates

Condition: Respiratory Distress Syndrome
Interventions: Device: Nasal continuous positive airway pressure (nCPAP); Device: Laryngeal Mask Airway (LMA) to deliver surfactant
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified April 2013
The Intravascular Cooling in the Treatment of Stroke 2/3 Trial

Condition: Stroke, Acute
Interventions: Device: hypothermia; Other: Group1: IV t-PA and normothermia
Sponsors: University of California, San Diego; University of California, San Diego; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Condition: Peripheral T-cell Lymphoma
Intervention:
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013
Hyperbaric Oxygen Therapy in Chronic Traumatic Brain Injury or Post-Traumatic Stress Disorder

Conditions: Traumatic Brain Injury; Post-traumatic Stress Disorder
Intervention:
Sponsors: International Hyperbaric Medical Foundation; International Hyperbaric Medical Foundation
Recruiting - verified April 2013
Patient Registry Study of Berinert® in Normal Clinical Practice

Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2013
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Selexipag (ACT-293987); Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2013
INSIGHT Influenza Hospitalization Study (FLU 003)

Conditions: Influenza; (Influenza A and Subtypes Such as H3N2 and 2009 H1N1 or Influenza B)
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified May 2013
INSIGHT Influenza Outpatient Study (FLU 002)

Condition: Influenza
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified May 2013
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified May 2013
Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia

Condition: Bronchopulmonary Dysplasia
Intervention: Drug: Infasurf surfactant (ONY, Inc.)
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: Coreg CR®; Drug: lisinopril; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified January 2013
Red Cell Storage Duration Study

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Interventions: Biological: Red blood cell units stored <= 10 days; Biological: Red blood cell units stored >= 21 days
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis

Conditions: Granulomatosis With Polyangiitis (Wegener's) (GPA); Microscopic Polyangiitis (MPA)
Interventions: Procedure: Plasma Exchange; Drug: Glucocorticoids
Sponsors: University of Pennsylvania; University of Pennsylvania; Food and Drug Administration (FDA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Birmingham Clinical Trials Unit; Cambridge University Hospitals NHS Foundation Trust
Recruiting - verified May 2013
Statins for Acutely Injured Lungs From Sepsis

Condition: Sepsis Induced ALI
Interventions: Drug: Rosuvastatin; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2013
Stem Cell Related Donor Safety Study

Condition: Related Hematopoietic Stem Cell Donors
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Institutes of Health (NIH); University of Utah; University of Pittsburgh
Recruiting - verified May 2013
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Prostate Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: cisplatin; Other: placebo; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Assessment of Screening Modalities for Gynecologic Cancers

Conditions: Ovarian Cancer; Endometrial Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2012
Strategic Timing of Antiretroviral Treatment

Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; The Kirby Institute for Infection and Immunity in Society; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified May 2013
Progesterone for the Treatment of Traumatic Brain Injury

Condition: Traumatic Brain Injury
Intervention: Drug: Progesterone
Sponsors: Emory University; David Wright
Recruiting - verified May 2013
CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass

Condition: Heart Failure
Intervention: Device: CentriMag Ventricular Assist System
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Conditions: Multiple Myeloma; Plasma Cell Neoplasm
Interventions: Drug: Group A=30-60 CrCl (mL/min); Drug: Group B=CrCL<30 mL/min not on dialysis; Drug: Group C=CrCL<30 mL/min and on dialysis
Sponsors: PrECOG, LLC.; PrECOG, LLC.; Celgene Corporation
Recruiting - verified May 2013
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013
Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Conditions: Non-small Cell Lung Cancer; Squamous Lung Dysplasia
Interventions: Drug: inositol; Other: placebo
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
AngelMed for Early Recognition and Treatment of STEMI

Conditions: Acute Myocardial Infarction (AMI); Coronary Occlusion; Acute Coronary Syndrome
Intervention: Device: AngelMed Guardian System
Sponsors: Angel Medical Systems; Angel Medical Systems; Symbios Clinical
Recruiting - verified May 2013
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); BSN Medical Inc; Genentech; Covidien; BayerHealthcare; Mid America Heart Institute; Society of Interventional Radiology Foundation; Massachusetts General Hospital
Recruiting - verified May 2013
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Conditions: Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Natural History Study of Hexosaminidase Deficiency

Condition: Tay-Sachs Disease, Sandhoff Disease, Late Onset Tay-Sachs Disease
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Rare Diseases Clinical Research Network; National Center for Advancing Translational Science (NCATS); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2013
Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified April 2013
Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery

Condition: Perioperative Inflammatory Response
Interventions: Drug: simvastatin; Drug: placebo
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified April 2013
Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed By Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: fludarabine phosphate; Procedure: hematopoietic stem cell transplantation; Drug: methylprednisolone; Drug: filgrastim; Drug: cyclosporine; Drug: Mycophenolate Mofetil
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2013
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Conditions: Crohn's Disease; Ulcerative Colitis; Indeterminate Colitis; Inflammatory Bowel Diseases
Interventions: Biological: Anti TNF therapy including infliximab; Drug: No Biologics
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: prednisone; Drug: thalidomide; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Induction Chemotherapy; Drug: Low-Risk Therapy; Drug: High-Risk Therapy; Drug: Intermediate-Risk Therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; University of Florida
Recruiting - verified May 2013
Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus

Conditions: Barrett's Esophagus; Early Esophageal Adenocarcinoma
Intervention:
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
The Effect of Ablation Therapy on Barrett's Esophagus

Conditions: Barrett's Esophagus; Early Esophageal Adenocarcinoma
Intervention: Biological: Biopsy
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2013
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: adult human mesenchymal stem cells; Drug: Placebo
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2013
Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care

Condition: Lumbar Degenerative Disc Disease
Interventions: Device: DIAM™ Spinal Stabilization System; Procedure: Conservative care
Sponsors: Medtronic Spinal and Biologics; Medtronic Spinal and Biologics
Recruiting - verified April 2013
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified May 2013
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2013
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Conditions: Systemic Sclerosis; Scleroderma; Pulmonary Hypertension; Pulmonary Arterial Hypertension
Intervention:
Sponsors: Georgetown University; Georgetown University; Gilead Sciences
Recruiting - verified May 2013
Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater

Condition: Optic Nerve Diseases
Intervention: Drug: Zyvox - linezolid
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer

Conditions: Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
Interventions: Biological: ziv-aflibercept; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Condition: Epilepsies, Partial
Interventions: Drug: Lyrica (pregabalin); Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2013
Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.

Conditions: Seizures; Epilepsies, Partial; Epilepsy, Complex Partial; Epilepsy, Generalized; Epilepsy
Interventions: Drug: Placebo; Drug: Vanquix Auto-Injector (Diazepam Injection)
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); NCIC Clinical Trials Group
Recruiting - verified May 2013
Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)

Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
Stem Cell Transplant for Hemoglobinopathy

Conditions: Sickle Cell Disease; Thalassemia; Severe Congenital Neutropenia; Diamond-Blackfan Anemia; Shwachman-Diamond Syndrome
Interventions: Drug: Busulfan, Fludarabine, ATG, TLI; Drug: Busulfan, Cyclophosphamide, ATG, GCSF; Drug: Campath, Fludarabine, Cyclophosphamide; Radiation: Total Body Irradiation; Procedure: Stem cell infusion
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; National Marrow Donor Program
Recruiting - verified May 2013
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: B-cell Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia
Interventions: Biological: rituximab; Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2013
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2013

Find Paid Research Studies in Minnesota

Welcome to Paid Research Studies.